We rank companies based on fund manager, research analyst and news sentiment
ATHA stock icon

Athira Pharma
ATHA

$2.13
3.4%
 

About: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Employees: 67

0
Funds holding %
of 6,474 funds
Analysts bullish %
0
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

6,100% more call options, than puts

Call options by funds: $768K | Put options by funds: $12.4K

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

23% more capital invested

Capital invested by funds: $43.3M [Q3] → $53.2M (+$9.89M) [Q4]

1.2% more ownership

Funds ownership: 56.31% [Q3] → 57.51% (+1.2%) [Q4]

10% less funds holding

Funds holding: 70 [Q3] → 63 (-7) [Q4]

20% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 20

58% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 12

Research analyst outlook

We haven’t received any recent analyst ratings for ATHA.

Financial journalist opinion

Based on 3 articles about ATHA published over the past 30 days